Even though it is known for more than one decade that antigen-encoding RNA can deliver antigenic information to induce antigen-specific immunity against cancer, the nature and mechanism of RNA uptake have remained enigmatic. In this study, we investigated the pharmacokinetics of naked RNA administered into the lymph node. We observed that RNA is rapidly and selectively uptaken by lymph node dendritic cells (DCs). Furthermore, in vitro and in vivo studies revealed that the efficient internalization of RNA by human and murine DCs is primarily driven by macropinocytosis. Selective inhibition of macropinocytosis by compounds or as a consequence of DC maturation abrogated RNA internalization and delivery of encoded antigens. Our findings imply that bioavailability of recombinant RNA vaccines in vivo highly depends on the density and the maturation stage of DCs at the administration site and are of importance for the design of RNA-based clinical immunotherapy protocols. Gene Therapy (2011) Keywords: vaccination; dendritic cells; RNA; macropinocytosis INTRODUCTION Antigen-encoding RNA has emerged as an attractive new vaccine format. Major advantages of RNA are efficient delivery of the complete antigenic information, transient expression and lack of genome integration, as well as cost-efficient and easy production in large amounts and high purity. 1 Moreover, through activation of the immune system via TLR3, TLR7 and TLR8, 2,3 RNA supports the induction of immune responses against the encoded protein.
INTRODUCTION
Antigen-encoding RNA has emerged as an attractive new vaccine format. Major advantages of RNA are efficient delivery of the complete antigenic information, transient expression and lack of genome integration, as well as cost-efficient and easy production in large amounts and high purity. 1 Moreover, through activation of the immune system via TLR3, TLR7 and TLR8, 2, 3 RNA supports the induction of immune responses against the encoded protein.
Of several in vitro and in vivo strategies utilizing antigen-encoding RNA as a vaccine format, 4 two are in clinical stage. One is based on adoptive transfer of autologous dendritic cells (DCs) transfected ex vivo with antigen-encoding RNA. [5] [6] [7] The other employs direct injection of naked RNA. 8, 9 Feasibility and safety of vaccination protocols based on intradermal administration of naked RNA have been shown in preclinical and clinical settings and partial protection from tumor challenge has been achieved in mice. 10, 11 However, at present, neither in animals nor in men, systemic immune responses let alone therapeutic effects were unequivocally demonstrated. It is assumed that rapid degradation by ubiquitous RNAses constraining pharmacologically efficient dosing of unprotected RNA contributes to the still suboptimal clinical effects. Knowledge about the nature and pharmacokinetics of RNA uptake in vitro and in vivo as well as the cell-type specificity is still scarce. Recently, we discovered that the administration route of naked RNA has a crucial impact on its efficacy as a vaccine. By injecting RNA directly into lymph nodes of mice, we achieved for the first time strong systemic antigen-specific Th1 type immunity and cancer cure in preclinical animal models. 12 The objective of the current study was to explore the mechanism by which RNA is uptaken and translated in the lymph node compartment as a model for understanding in vivo RNA pharmacology in general. We revealed for the first time that macropinocytosis has a dominant role in this process. These findings are of high relevance for optimization of vaccination strategies using RNA as active pharmaceutical ingredient.
RESULTS

RNA is selectively and efficiently taken up by DCs
We have recently observed that naked antigen-encoding RNA injected into lymph nodes of mice is efficiently taken up, ensuring high bioavailability of the encoded antigen. 12 In continuation of that work, we investigated the kinetics of RNA uptake by injecting Cy5-labeled RNA (Cy5-RNA) into inguinal lymph nodes of mice. Phenotyping of cell suspensions from inguinal lymph nodes harvested 1 h after injection of Cy5-RNA by flow cytometry confirmed our previous observation 12 of exclusive enrichment of RNA in CD11c + CD8 + and CD11c + CD11b + subpopulations of lymph node DCs (Figure 1a) , which are known to be efficient stimulators of lymph node T cells. 13 Luciferaseencoding RNA (Luc-RNA) injected intranodally, as well, was exclusively internalized by lymph node resident DCs in vivo as revealed by luciferase activity of sorted cell populations (Figure 1b) .
To verify DC specificity of uptake in vitro, B and T cells and DCs harvested from inguinal lymph nodes and MFs retrieved from intraperitoneal cavities of C57BL/6 mice were co-incubated in small volumes (10-20 ml) of Luc-RNA. Again, uptake measured as luminescence was highest in DCs, significantly lower in macrophages and not detectable at all in lymphocytes (Figure 1c) .
Analogous findings were made upon in vitro pulsing of the human counterparts of these cell types. Human DCs derived from blood monocytes, but not macrophages or peripheral blood lymphocytes showed the highest capability of internalizing RNA (Figure 1d ) and delivering the encoded protein (Figure 1e ), suggesting a selective and species-spanning uptake mechanism of RNA into professional antigen-presenting cells (APCs).
RNA uptake in DCs is governed by macropinocytosis Next, we focused on the mechanisms responsible for the exclusive accumulation of RNA in DCs. RNA uptake by immature human DCs (iDCs) in vitro was found to be dose and temperature dependent (Figures 2a and b) , implying the involvement of active cellular processes. Remarkably, Luc-RNA amounts as little as 10 ng generated luminescence signals significantly above background. No saturation of the uptake mechanism was observed along three orders of magnitude with RNA amounts of up to 30 mg. The uptake of RNA by iDCs was extremely fast, and protein was detected a few minutes after pulsing (Figure 2c) .
A characteristic feature of iDCs is constitutive macropinocytosis. 14 In this process, large vesicles are formed by actin-driven evaginations of the plasma membrane and incorporate large quantities of fluidphase solid from the extracellular space. 15 To explore the involvement of this process in RNA internalization, we performed co-localization studies with fluorescein isothiocyanate (FITC)-Dextran, which is taken up by both macropinocytosis and mannose-receptor-dependent pathway and with Lucifer Yellow (LY), which is solely internalized by macropinocytosis. Fluorescence microscopy of human iDCs pulsed with either of these tracers and Cy3-RNA showed large, doublepositive vesicles within few minutes after Cy3-RNA pulsing of iDCs (Figure 3a ). Co-localization was partial with FITC-Dextran, complete with LY and negative with clathrin, a classical receptor mediated endocytosis marker. 16 Treatment of human iDCs with inhibitors of fluid-phase endocytosis such as dimethyl-amiloride, cytochalasin D, LY294002 and rottlerin 17, 18 before Cy3-RNA pulsing dramatically reduced the signal intensity and number of vesicles internalizing Cy3-RNA (Figure 3b) as well as the luciferase activity (Figure 3c ). Nearly complete blocking of RNA uptake was achieved with rottlerin, which among the used compounds has the highest selectivity for macropinocytosis and leads to irreversible blockade of the process. 19 When human MFs were treated with PMA, which is known to strongly induce macropinocytosis in these cells, 20 before pulsing with Luc-RNA, substantial increase of the luciferase signal was achieved. In contrast, PMA treatment did not affect luciferase signal obtained after electroporation of Luc-RNA (Figure 3d ). Having shown that Selective uptake of vaccine RNA by DCs via macropinocytosis M Diken et al macropinocytosis is involved in uptake of RNA by APCs in culture, we investigated its role in vivo for internalization of RNA administered into lymph nodes of mice. Pretreatment of lymph nodes with rottlerin before injection of Luc-RNA resulted in a marked reduction of luciferase activity as detectable by in vivo bioluminescence imaging ( Figure 3e) . As a consequence, rottlerin pretreatment of lymph nodes diminished dramatically the frequency of SIINFEKL-specific CD8 + T cells induced de novo in C57BL/6 mice immunized intranodally with SIINFEKL-RNA encoding an ovalbumin epitope (Figure 3f ). Effects of rottlerin on cell viability, on translation or on the antigenprocessing machinery were excluded (Supplementary Figure 1) .
In summary, our data reveal a dominant role of macropinocytosis in the uptake of RNA by APCs.
RNA uptake in vitro and in vivo is abrogated by DC maturation The findings above predict an impact of biological stimuli that alter the level of macropinocytotic activity in DCs on delivery of the RNAencoded protein. As maturation of DCs by inflammatory signals is known to be associated with loss of constitutive macropinocytosis, 14 we studied the dependence of RNA uptake on the differentiation stage of DCs. Treatment of human DCs (Figures 4a and b) and of murine bone marrow-derived DCs (Figures 4c and d) with maturation stimuli such as poly inosinic:poly cytidylic acid (Poly I:C), lipopolysaccharide (LPS) or CD40L resulted in almost complete cessation of internalization as measured by two independent read-out systems.
We then tested whether these effects were reproducible in vivo. Subcutaneous injection of Poly I:C into the draining area of the inguinal lymph node of BALB/c mice at different time points before intranodal administration of Luc-RNA resulted in a massive drop of RNA internalization-dependent bioluminescence signals (Figure 4e ). The reduction of uptake correlated with the stage of maturation of CD11c + lymph node DCs as demonstrated by progressive upregulation of the activation marker CD86 and resulted in a nearly complete loss of RNA uptake capacity 24 h after initiation of the maturation process (Figure 4f; Supplementary Figure 2) , further confirming the role of macropinocytosis.
DISCUSSION
We present in this study the first systematic analysis of in vivo pharmacokinetics of antigen-encoding RNA after direct application. We recently revealed that the intranodal route for RNA vaccination ensures potent induction of antigen-specific T-cell immune responses and antitumor immunity. 12 Surprisingly, the superiority of this administration route was found to be attributable to a rapid active uptake and translation of RNA exclusively by lymph node resident DCs. Using luciferase-encoding RNA as reporter, we found that murine and human DCs are highly efficient in incorporating RNA from extracellular fluids and translating it. This process is very fast and the encoded protein is detectable within minutes. Moreover, RNA uptake is scalable and the RNA dose/response relationship increases linearly over more than four dose logs. This exquisite cell-type selectivity and uptake properties have fundamental implications for in vivo application of RNA. For RNA as vaccine format it is highly beneficial that efficient internalization of RNA by professional APCs is a spontaneous and genuine process. Gene therapies that use RNA to substitute for molecular deficiencies, in contrast, would require dedicated delivery systems to prevent uptake by immunogenicitypromoting DCs and to target other cell types.
Although it is known for more than one decade that antigenencoding RNA co-incubated with APCs, is internalized and translated, 21 surprisingly few data are published on the underlying mechanisms in vitro and in vivo. The only study that investigated the uptake of RNA in vivo proposed a saturable Ca +2 ion-dependent process without defining the exact mechanism and cell type. 22 Similarly, for other naked nucleic acid based compounds, there is a lack of knowledge on mechanisms of internalization by APCs. For siRNA only uptake by metazoan cells has been studied, 23 whereas for plasmid DNA circumstantial evidence supports the hypothesis of uptake into macrophages via scavenger receptor A. 24 Our findings revealed for the first time that in vitro as well as in vivo this efficient internalization process of RNA is primarily driven by macropinocytosis. Professional phagocytes such as DCs and macrophages are able to efficiently internalize RNA by this mechanism. Neither the length nor the sequence composition of RNA altered the uptake mechanism as revealed by use of RNAs differing in length and sequence (Luc-RNA, HA-RNA, SIINFEKL-RNA). Selective inhibition of this mechanism stops internalization of RNA and almost completely eliminates bioavailability of encoded antigens in DCs. Macropinocytosis had never been shown before to be involved in internalization of any naked nucleic acid based compound into APCs. Our finding that presentation of the RNA-encoded antigen at levels sufficient for priming of Selective uptake of vaccine RNA by DCs via macropinocytosis M Diken et al naive T cells relies completely on macropinocytosis, highlights the in vivo relevance of this uptake mechanism for the efficacy of RNA as a vaccine.
Another key finding of this study is that when DCs were prestimulated with well-known maturation-inducing adjuvants such as LPS, dsRNA or CD40L, in vitro and in vivo uptake of RNA and the bioavailability of encoded antigens were abrogated. This finding is of high importance as it implicates restriction of RNA uptake to DCs with immature phenotype, since constitutive macropinocytotic activity of DCs is known to be abolished by maturation stimuli. 14, 25 This observation is also of profound relevance for clinical protocols combining naked RNA with maturation-inducing adjuvants. According to our findings, these should not been administered simultaneously to avoid imperilment of immune response induction. It is noteworthy that proper expression and presentation of the encoded antigen requires the escape of RNA from the macropinosomes. Even though endosomal compartments appear to be leaky or possess channels or transporters facilitating the egression and cross presentation of antigens from endosomes [26] [27] [28] [29] [30] the penetration mechanisms of RNA through the endocytic membrane remain to be investigated.
Taken together, this study provides an in-depth characterization of the uptake of antigen-encoding RNA by DCs and gives novel insights in cell type and mechanism ruling this process in vitro and in vivo. These findings may pave the way for rational design of vaccines based on naked antigen-encoding RNA.
MATERIALS AND METHODS Animals
C57BL/6 and BALB/c mice were purchased from Jackson Laboratories (Sulzfeld, Germany). C57BL/6 Thy1.1 + mice were kindly provided by HJ Schild (University of Mainz, Germany).
Cells
C57BL/6 bone marrow-derived DCs generated as previously described 31 were matured with Poly I:C (50 mg ml -1 ; InvivoGen, Toulouse, France) or LPS (50 ng ml -1 ; Sigma, Taufkirchen, Germany) for 40 h. Murine B and T cells were isolated from lymph node cell suspensions by magnetic activated cell sorting (MACS) technology (Miltenyi Biotec, Bergisch Gladbach, Germany). Murine macrophages were obtained from the intraperitoneal cavity. iDCs were differentiated from purified CD14 + monocytes as described previously 32 and matured with human soluble CD40L (0.75 mg ml -1 ; Alexis Biochemicals, San Diego, CA, USA), Poly I:C (50 mg ml -1 ) or LPS (20ngml -1 ). Human macrophages (MF) were generated by 5-day culture of CD14 + monocytes in DC medium containing 5% heat-inactivated AB-Serum (Lonza, Cologne, Germany). 33 
RNA constructs
Plasmid templates for in vitro transcription of naked antigen-encoding RNAs were based on pSTI-A120 and pSTI-MITD vectors. 34 pSTI-MITD features a signal sequence for routing to the endoplasmic reticulum and the major histocompatibility complex (MHC) class I transmembrane and cytoplasmic domains for improved presentation of MHC class I and II epitopes. 34 pSTI-eGFP-120 (enhanced green fluorescence protein (eGFP)), pSTI-SIIN-FEKL-MITD (SIINFEKL), pSTI-Influenza-HA-MITD (HA) and pSTI-Luciferase-A120 (Luc) vectors were described previously. [34] [35] [36] SIINFEKL construct encodes for the dominant epitope (aa 257-264) of chicken Ovalbumin, and HA construct contains a codon optimized partial sequence of influenza haemagglutinin (aa 60-285 fused to aa 517-527; influenza strain A/PR/8/34) designed to combine all major immunodominant MHC epitopes.
In vitro transcription, labeling of RNA and transfer into cells RNA was generated by in vitro transcription as described previously. 32 Labeling of RNA with Cy3-UTP or Cy5-UTP was conducted according to the manufacturer's instructions (Amersham Biosciences, Buckinghamshire, UK) using the pSTI-Influenza-HA-MITD (HA) vector as template.
For in vitro pulsing, 1-3Â10 6 cells were pelleted and incubated with RNA in RNase-free phosphate-buffered saline (Ambion, Austin, TX, USA) for 15 min in a volume of 10-20 ml and then cultivated in the respective medium at 37 1C with 5% CO 2 . For some experiments, DCs were treated with either LY294002 (50 mM; Calbiochem, Darmstadt, Germany), cytochalasin D (10 mM; Fluka, Deisenhofen, Germany), dimethyl-amiloride (500 mM; Sigma) or rottlerin (3-10 mM; Calbiochem) for 30 min at 37 1C before RNA pulsing. In some control experiments, RNA was electroporated as described previously. 34 
Intranodal immunization of mice
Mice were anesthetized and the inguinal lymph node was surgically exposed. In all, 10-30 mg RNA formulated in 10 ml RNase-free phosphate-buffered saline (Ambion) was injected slowly and the wound was closed. 12 In some experiments, rottlerin (10 mM in 10 ml) was injected into the lymph node 15 min before intranodal administration of the respective RNA.
Luciferase assay
Cells pulsed with RNA coding for firely luciferase (Luc-RNA) were incubated for 22 h at 37 1C and plated in 96-well white microplates (Nunc, Langenselbold, Germany). Lysis of cells was performed with 0.25% Triton X-100 (AppliChem, Darmstadt, Germany). D-Luciferin (1 mg ml -1 ; BD Pharmingen, Heidelberg, Germany) and 5 mM ATP-10 mM Tris base (AppliChem) were added to each well and bioluminescence flux was measured using a microplate luminescence reader (Infinite M200, Tecan Group, Männedorf, Switzerland) with 1 s integration time. Data were represented in counts per second (c.p.s.). The background luciferase values measured in cells that were not pulsed or pulsed with irrelevant RNA were within the range of 15 ± 5 c.p.s.
In vivo bioluminescence imaging
Bioluminescence imaging was performed using an IVIS Lumina imaging system (Caliper Lifesciences, Hopkinton, MA, USA) as described previously. 36 
Flow cytometric analysis
Monoclonal antibodies for flow cytometry were from BD Pharmingen. Lymph nodes were subjected to collagenase D (1 mg ml -1 ; Roche, Mannheim, Germany) treatment for 10 min, and thereafter suspensions were incubated at 4 1C for 30 min with specific monoclonal antibodies (mAbs). Quantification of the SIINFEKL peptide (Jerini Peptide Technologies, Berlin, Germany) presented on H-2K b molecule was performed as described previously. 34 MHC-peptide tetramer staining from blood samples was performed with H-2K b /SIINFEKL tetramer (Beckman Coulter, Brea, CA, USA) and CD8 antibody (Invitrogen, Carlsbad, CA, USA). 36 Flowcytometric data were acquired on a FACSCalibur flow cytometer and analyzed by FlowJo (Tree Star, Ashland, OR, USA) software.
Immunofluorescence
For co-localization studies, cells were co-pulsed with Cy3-RNA and either FITC-Dextran-70000 (1 mg ml -1 ) or LY (4 mg ml -1 ) (Invitrogen) for 10 min and then directly fixed with 4% paraformaldehyde after washing with phosphatebuffered saline. Clathrin staining was performed on permeabilized cells with mAB X22 (Abcam, Cambridge, MA, USA) and a FITC-labeled secondary Ab (Jackson Immunoresearch, Suffolk, UK). A Leica (Wetzlar, Germany) immunofluorescence microscope with a Â40/0.4 NA objective lens and the QFISH software (Leica) were used.
Total cellular fluorescence images were taken with an Olympus IX 70 (Hamburg, Germany) microscope with a Â40/0.55 NA objective lens. With the Till Vision Software 4.0 (Till Photonics, Graefelfing, Germany) arbitrarily chosen cells were defined as region of interest to measure total fluorescence and the background was subtracted using the same region moved to a cell-free area.
Statistics
Statistical analysis was performed by GraphPad Prism 4 software (La Jolla, CA, USA) employing unpaired two-tailed Student's t-test or analysis of variance with Tukey's multiple comparison test. P-values were provided and data are given as mean+s.d. or s.e.m.
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